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Detection of vascular endothelial growth factor in
colon cancer xenografts using bevacizumab
based near infrared fluorophore conjugate
Bishnuhari Paudyal1,2*, Pramila Paudyal2, Dilip Shah3, Hideyuki Tominaga2, Yoshito Tsushima2 and Keigo Endo2,4

Abstract
Background: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for
the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with
bevacizumab, and injected intravenously into nude mice bearing VEGF over-expressing HT29 human colorectal
cancer. Optical imaging was performed at 15 min, 24 h and 48 h post injection. Immunofluorescences staining
of the tumor sections were performed. HT29 colorectal cancer xenografts were clearly visualized with
bevacizumab-AlexaFluor 750.
Results: Ex vivo analysis showed 2.1 ± 0.4%, 37.6 ± 6.3% and 38.5 ± 6.2% injected dose/g accumulated in the tumors
at 15 min, 24 h and 48 h respectively. Tumor uptake was significantly decreased in pretreated with excess of
bevacizumab (p = 0.002). Immunofluorescence analysis showed strong staining of anti-CD 31 antibody around the
blood vessels. Anti-VEGF-A and bevacizumab showed heterogeneous expression throughout the tumor.
Conclusions: Current study successfully detected the VEGF expression in HT29 colorectal cancer xenografts,
signifying as a potential agent for non-invasive imaging of VEGF expression, which may be applied in
clinical practice.
Keywords: Near infrared fluorescence, VEGF, Optical Imaging, Bevacizumab, Colorectal cancer

Background
Molecular imaging has emerged as an indispensable tool in
the field of cancer research for in vivo monitoring of specific molecular and cellular processes, such as gene expression, multiple simultaneous molecular events, progression
or regression of cancer, reliable diagnostic imaging for
various malignancy, and it allows for functional assessment
of tumors [1-6]. Optical imaging is an emerging modality of
choice for preclinical studies to evaluate the expression of
different kinds of proteins. It allows visualization of subcellular structures on a microscopic scale, as well as macroscopic distribution of fluorescent labels in vivo in small
animals [7]. However, high tissue auto fluorescence and
limited tissue penetration preclude the use of visible light
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for most in vivo imaging applications. Near infrared (NIR)
light solves these problems by reducing fluorescence background and enhancing tissue penetration [8-10].
Over the past several years, there has been an explosion of reports describing successful in vivo NIR fluorescence imaging [11-18]. Several optical contrast agents
have been developed for the detection of various types
of cancer [19-21]. Although most of these studies are
qualitative, quantitative studies are beginning to emerge.
Vascular endothelial growth factor (VEGF) is upregulated in numerous solid malignancies including colon
cancer. VEGF induces and the formation of vesiculovacuolar organelles that form channels through which
blood-borne proteins can extravasate. This leads to the
formation of an extravascular fibrin gel, which provides
a matrix that supports the growth of endothelial cells
and tumor cells and allows invasion of stromal cells into
the developing tumor [22]. Several studies have implicated VEGF in human colon cancer angiogenesis [23].
However, the increased in VEGF expression has been
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associated with poor prognosis. VEGF overexpression is
seen in most cancers, providing an attractive target for
molecular therapies [17,24-27]. One of the most successful approaches is the development of bevacizumab,
a humanized monoclonal antibody targeting VEGF [28].
Bevacizumab binds with all VEGF-A isoforms and prevents interaction with the VEGF-A receptors, VEGFR-1
and VEGFR-2, and thus inhibits VEGF-mediated angiogenesis [15]. The present study evaluated the feasibility of
using NIRF-labeled bevacizumab for tumor imaging in
colon cancer xenografts. Bevacizumab was labeled with
NIRF agent, and the optical imaging and biodistribution
of the conjugate were investigated in nude mice bearing
VEGF overexpressing HT29 colorectal cancer xenografts.

Methods
Cell lines

Human colorectal cancer cell line HT29 was purchased
from American Type Culture (Rockville, USA) and was
cultured in McCoy’s medium (Sigma, St Louis, MO, USA)
supplemented with 10% fetal bovine serum and antibiotics
(100 U/ml penicillin and 100 μg/ml streptomycin).
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counted from three randomized fields per tumor section at a magnification of 200× under the fluorescence
microscope.
In vivo tumor model

Animal experiments were conducted in accordance with
Gunma University institutional guideline and were approved by the Animal Care and Use Committee. Female
Balb/c nude mice, 6 weeks old (CLEA, Tokyo, Japan)
were maintained under specific pathogen-free conditions
and were provided with sterile food and water. Nude
mice were inoculated subcutaneously with VEGF expressing HT29 cells. When the tumors were 7–8 mm in
diameter, the animals were injected intravenously with
50 μg of bevacizumab-AlexaFluor 750. For competitive
blocking studies, another group of mice (n = 4) were pretreated with excess fold of unconjugated bevacizumab
before administering the fluorescently labeled bevacizumab. Blood was withdrawn from the tail veins of xenografted mice to determine the concentration of VEGF in
serum. Mice were examined by optical imaging.
Fluorescence imaging

Reagents

Bevacizumab (Avastin®, Chugai Pharmaceuticals, Tokyo,
Japan) was conjugated with SAIVI AlexaFluor 750, 3 mg
labeling kits (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol. Briefly, 3 mg/ml of the
bevacizumab was mixed with sodium bicarbonate and
conjugated with Alexa Fluor 750. The purification of labeled antibody was performed in a spin column filled
with size exclusion resin in PBS, pH 7.2. Spectrophotometer was used to analyze the moles the stoichiometry
of dye-to-protein was estimated from absorbance according to the protocol from Invitrogen. The fluorescent
protein was aliquoted and stored in the dark at room
temperature.
Immunofluorescence studies

Frozen tissue slides were fixed in ice-cold acetone and
were fixed with 4% paraformaldehyde for 15 min at room
temperature, and blocked with 3% BSA in PBS for 1 h at
room temperature. The specimens were then incubated
with rat anti-mouse CD 31 antibody (PEGAM-1; BectonDickinson, Harlingen, CA, USA), anti-mouse VEGF-A
(BioLegend, CA, USA), and bevacizumab for 1 h at room
temperature. After thoroughly washing with PBS, the
slides were visualized with AlexaFluor 488 (Invitrogen,
Carlsbad, CA, USA) for 1 h at room temperature. Mounting medium with DAPI (Vector, CA, USA) was used to fix
and stain the cell nuclei. The cells were then observed
under a fluorescence microscope (Olympus BX50, Tokyo,
Japan). Average microvessel density (MVD) was calculated
by averaging the number of CD31-positive vessel structures

The in vivo optical imaging was carried out with a small
animal in vivo imaging system (Maestro CRI, MA, USA).
The animals were anesthetized with 10% pentobarbital
sodium before the acquisition was started. A customized
filter set (excitation, 710–760 nm; emission, 695–800 nm)
was used for NIRF data acquisition. A group of 4 mice
were used at each time point for the experiments. The
biodistribution of fluorescence intensity was monitored at
15 min, 24 h and 48 h post-injection. In order to quantitatively estimate the accumulation of the probe in selected
organs, animals were killed by decapitation. Tissues of
interest were excised and weighed. The fluorescence intensity of each tissue was measured and normalized to
photons per second with an ROI covering the entire tissue. The total fluorescence flux of each tissue was divided
by its weight. The results were calculated as % injected
dose/gram (% ID/g).
Statistical analysis

Data were expressed as mean ± standard deviation. Means
were compared using unpaired student’s t-test. P values of
less than 0.05 were considered statistically significant.

Results
Synthesis and characterization of bevacizumab-AlexaFluor
750

The molar ratio of AlexaFluor 750 to bevacizumab was
determined to be 2:1. The absorption and fluorescence
emission characteristics of the bevacizumab-AlexaFluor
750 was found to be similar to those of free AlexaFluor
750, as apparent from the spectra measured in PBS,
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suggesting that the fluorescence property of the AlexaFluor 750 was not affected by the conjugation to the
bevacizumab.
In vivo imaging studies with bevacizumab-AlexaFluor 750

Figure 1 shows NIR fluorescence images of mice bearing
VEGF positive HT29 tumors at 15 min (a-b), 24 h (c-d),
and 48 h (e-f). In vivo fluorescence detection revealed distinct uptake in the VEGF overexpressing HT29 tumors at
24 h and 48 h after the IV injection of bevacizumabAlexaFluor 750. The fluorescence signal was clearly visualized in the tumor area as compared with normal regions.
The HT29 tumor bearing xenografts pretreated with excess fold of bevacizumab Figure 2(b) showed a significant
(p = 0.002) decrease in the accumulation of bevacizumabAlexaFluor 750 in comparing with untreated tumor
Figure 2(a), illustrating the specificity that completely block
the bevacizumab-Alexa Fluor750. Quantitative analysis
of the ex vivo tissue fluorescence images post-injection
with bevacizumab-AlexaFluor 750 (Figure 3) demonstrates
the progressive accumulation of bevacizumab-AlexaFluor
750 by the VEGF positive HT29 tumors (2.1 ± 0.4% ID/g),

Figure 2 The tumor and serum (the representative HT29 tumor
bearing mouse) was pretreated with excess fold of
bevacizumab: tumor VEGF (a-b) and serum VEGF (c-d). Tumor
VEGF in the pretreated group of mice is significantly (p = 0.002)
suppressed (b) in the accumulation of bevacizumab-AlexaFluor 750
in comparing with untreated tumor Figure 2(a), while the serum
VEGF is relatively higher (d) comparing to the untreated serum (c).

(37.6 ± 6.3% ID/g) and (38.5 ± 6.2% ID/g) at 15 min, 24 h
and 48 h respectively, post injection. The tumor to blood
ratio was 1.3 ± 1.1 at 24 h. and 1.5 ± 1.2 at 48 h. Intense
fluorescence was seen in the blood and blood-rich organs like lung (78.5 ± 13.8% ID/g) and liver (76.8 ± 3.0%
ID/g) at 15 min, which decreased at 24 h to 19.2 ± 3.0%
and 48 h to 29.6 ± 5.3% ID/g, respectively (Figure 3).
The fluorescence intensity in muscle and other nontarget regions were nominal.
Immunofluorescence studies

Figure 1 NIRF images of HT29 human colon cancer bearing
mice obtained at 15 min (a-b), 24 h (c-d) and 48 h (e-f) after
intravenous injection of bevacizumab-AlexaFluor 750. Arrows
indicate tumor, L: Liver, I: Intestine, S: Stomach, Sp: Spleen, P:
Pancreas, Lu: Lung, H: Heart, M: Muscle, B: Bone, Br: Brain.

To characterize the localization of VEGF, histological analysis of the tumor specimens was performed using antiCD31, anti-VEGF-A, and bevacizumab. Figure 4(a-c)
shows the expression of CD 31 and VEGF. Strong staining
by the anti-CD31 antibody is noted around the blood
vessels formed within the tumor section. The expression
pattern of VEGF was heterogeneous throughout the
cytoplasm. Both bevacizumab and anti-VEGF-A showed
similar cytoplasmic staining, suggesting the binding of
both antibodies to the VEGF antigen. A significant correlation was obtained between the bevacizumab-AlexaFluor
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Figure 3 Biodistribution studies of bevacizumab-AlexaFluor
750 in HT29, human colon cancer bearing mice at 15 min, 24 h
and 48 h. Data compare in percent injected dose per gram in the
organs after injection with bevacizumab-AlexaFluor 750. Tumor
uptake reached the peak at 24 h.

750 % ID/g uptake of the tumors and their respective
MVD (p = 0.01, r2 = 0.89), as shown in Figure 5.

Discussion
The present study reports the development and validation of the bevacizumab-AlexaFluor 750 conjugates
as a NIRF imaging agent for noninvasive imaging of
VEGF expression in human colon cancer xenografts in
mice. In vivo assessment of VEGF within a tumor using
bevacizumab-AlexaFluor 750 offers further information
about the angiogenic activity of the tumor.
Here we showed a significant VEGF specific accumulation of bevacizumab-AlexaFluor 750 in the tumor region.
Immunofluorescence microscopy with anti-VEGF-A and
bevacizumab showed heterogeneous expression throughout the cytoplasm of HT29 cells. The presence of adequate
microvessels was noted when the slides were incubated
with anti-CD31 antibody, which might have contributed to the higher accumulation of the bevacizumabAlexaFluor 750. A significant linear correlation was noted
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Figure 5 Significant correlation is noted (p = 0.01, r2 = 0.89),
between the presences of average micro vessel density in
three random fields and the tumor uptake as measured by
% ID/g.

between the MVD and the tumor accumulation as determined by % ID/g, in agreement with the role of VEGF
in angiogenesis. The mice treated with excess folds of
bevacizumab before the administration of bevacizumabAlexaFluor 750 showed decreases in serum than those
without pretreatment however the difference was not
significant. This discrepancy may be due to the fact
that, even though the energy absorbed due to water or
other naturally occurring fluorochromes is low at the
near infrared window, the sensitivity is not as high as it
is in the case of hemoglobin, suggesting its limited use
as a primary imaging modality.
Generally, serum VEGF is measured to monitor the
VEGF expression before the initiation of therapy however VEGF concentration determined from circulation
are invasive and are obscure due to the fact that circulating VEGF not only measures the tumor VEGF but also
the VEGF secreted by platelets, granulocytes, monocytes,
mast cells, and lymphocytes which might give a false
positive result [29]. Understanding the complex role of
VEGF in tumor development has been somewhat limited

Figure 4 Immunofluorescence staining of HT29 tumor with: (a) anti-CD 31 antibody (400×), (b) anti-VEGF-A antibody (800×), and (c)
bevacizumab (800×) in frozen sections (Green: antibody labeled AlexaFluor 488, blue is DAPI).
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by the absence of methods to measure this cytokine
spatially and temporally [30]. There is a need for the development of noninvasive imaging to allow monitoring
of angiogenesis related molecular events. Reliable markers
that can predict which patients are more likely to respond
to anti-VEGF therapy would be important, but they have
been elusive so far.
Few studies have documented the ability to image VEGF
in vivo using radiolabeled bevacizumab [31-34]. Recently,
Scheer et al. found no correlation between the level of
antibody accumulation and expression of VEGF, measured
by ELISA in the liver metastasis [35]. Even though these
studies possess useful information on the diagnosis, imaging with radiolabeled compounds requires expensive
equipment and exposes patients to ionizing radiation. Optical imaging is emerging as a sensitive, specific, inexpensive, and convenient technology that permits the study
of a variety of cellular and molecular processes in vivo.
Earlier studies reported that NIR fluorophores can be detected 7–14 cm deep in tissue [9]. Nevertheless, it suffers
from poor detectability due to low tissue penetration. This
inspection, together with our results and the continued
development of versatile imaging devices, could overcome
these issues and therefore make optical imaging the modality of choice.
In clinical settings, optical imaging is relevant for tissues close to the surface of the skin, tissues accessible by
endoscopy, and intraoperative visualization. Multimodality imaging approach can be developed such as further
labeling of bevacizumab-AlexaFluor 750 with radionuclides for PET and SPECT as well as a contrast agent for
MRI to enhance the sensitivity and specificity of biomedical imaging in vivo.
The large size of an antibody impacts its ability to move
through a tumor mass. A high interstitial pressure inhibits
the diffusion of larger molecules within the tumor migration within the tumor is also inhibited by a binding site
barrier [35-37]. Administering higher doses of the antibody can reduce the effect of the binding site barrier and
allow the antibody to diffuse more deeply into the tumor
bed [37]. The present study showed that the tumor uptake
of bevacizumab-AlexaFluor 750 in HT29 xenografts was
high, and lower in the non-targeted tissues. The high
tumor accumulation is the most important property of the
optical imaging tracer. These results warrant the further
assessment of this bevacizumab-AlexaFluor 750 for imaging in colon cancer and other tumor models.

Conclusions
In conclusion, we could successfully detect the VEGF expressing tumors using bevacizumab-AlexaFluor 750 in vivo.
Because the majority of tumor vasculature overexpresses
VEGF during angiogenesis, bevacizumab-AlexaFluor 750
has great potential for detecting tumor vasculature in vivo
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in general for most cancer types. The results reported here
open up new perspectives for VEGF-targeted imaging in a
less expensive way.
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